A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer

BACKGROUND: In this open-label phase I study, the maximum-tolerated dose of cetuximab with concurrent chemoradiotherapy (C-CRT) in stage III non–small-cell lung cancer together with individualized, isotoxic accelerated radiotherapy (RT) was investigated. METHODS: Patients with stage III non–small-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Dingemans, Anne-Marie C., Bootsma, Gerben, van Baardwijk, Angela, Reymen, Bart, Wanders, Rinus, Brans, Boudewijn, Das, Marco, Hochstenbag, Monique, van Belle, Arne, Houben, Ruud, Lambin, Philippe, de Ruysscher, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132032/
https://www.ncbi.nlm.nih.gov/pubmed/24722157
http://dx.doi.org/10.1097/JTO.0000000000000151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132032/
https://www.ncbi.nlm.nih.gov/pubmed/24722157
http://dx.doi.org/10.1097/JTO.0000000000000151

Ejemplares similares